Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 144 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Taxotere® Clear all

Conditions: Breast Cancer, Breast Cancer Female
Interventions: Standard of Care: Docetaxel, Standard of Care: Cyclophosphamide, Function Assessment of Cancer Therapy (FACT) Surveys; Drug · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 65 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Prostate Cancer
Interventions: Cabazitaxel (XRP6258), Prednisone (or Prednisolone); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 21
States / cities: Muscle Shoals, Alabama • Hot Springs, Arkansas • Anaheim, California + 18 more

Conditions: Lung Cancer
Interventions: docetaxel, gefitinib, laboratory biomarker analysis, radiation therapy; Drug · Other · Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Advanced Solid Tumors
Interventions: BMS-986360, Docetaxel, Nivolumab, Capecitabine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 8
States / cities: Los Angeles, California • New Orleans, Louisiana • Hackensack, New Jersey + 4 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions: Pembrolizumab, Placebo for pembrolizumab, Carboplatin, Paclitaxel, Olaparib, Placebo for olaparib, Bevacizumab, Docetaxel; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 43
States / cities: Birmingham, Alabama • Tucson, Arizona • Burbank, California + 37 more

Conditions: Non Small Cell Lung Cancer
Interventions: IPI 504 plus Docetaxel, Placebo plus Docetaxel; Drug
Lead sponsor: Infinity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 41
States / cities: Chandler, Arizona • Tucson, Arizona • Orange, California + 38 more

Conditions: Breast Cancer
Interventions: Docetaxel, 5-fluorouracil, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 1,491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Cervix Neoplasm
Interventions: docetaxel, Radiation Therapy; Drug · Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Advanced Cancer, Advanced Malignancies
Interventions: Cemiplimab, Hypofractionated radiotherapy, Cyclophosphamide, Docetaxel, Carboplatin, GM-CSF, Paclitaxel, Pemetrexed; Drug · Radiation
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 40
States / cities: Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 31 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Bevacizumab (Avastin), Carboplatin, Docetaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Cancer
Interventions: CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection, CNTO888 + gemcitabine, CNTO888 + Paclitaxel and carboplatin, CNTO888 + docetaxel; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Detroit, Michigan • Tacoma, Washington

Conditions: Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
Interventions: Docetaxel, HyperAcute®-Lung Immunotherapy, Gemcitabine, Pemetrexed; Drug · Biological
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 24
States / cities: Santa Rosa, California • Stamford, Connecticut • Gainesville, Florida + 20 more

Conditions: Prostatic Neoplasms
Interventions: Docetaxel (TAXOTERE®) Chemotherapy, Leuprolide acetate ( ELIGARD®) Hormonal Therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Sacituzumab tirumotecan, Docetaxel, Pemetrexed; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 16
States / cities: Los Angeles, California • Jacksonville, Florida • Orange City, Florida + 13 more

Conditions: Breast Neoplasms
Interventions: Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2, Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2, Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2; Drug
Lead sponsor: R-Pharm; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 60
States / cities: Tuscaloosa, Alabama • La Jolla, California • Southington, Connecticut + 52 more

Conditions: Prostatic Neoplasms
Interventions: Docetaxel, PSK®, Docetaxel, Placebo; Drug
Lead sponsor: Bastyr University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostatic Neoplasms, Castration-Resistant
Interventions: Opevesostat, Olaparib, Docetaxel, Cabazitaxel, Fludrocortisone acetate, Dexamethasone, Prednisone; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 7
States / cities: La Jolla, California • Los Angeles, California • Miami, Florida + 4 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: docetaxel, gefitinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-small Cell Lung Cancer
Interventions: ezatiostat hydrochloride (Telintra®); Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 24
States / cities: Alhambra, California • Anaheim, California • Burbank, California + 20 more

Conditions: Solid Tumors
Interventions: Acasunlimab, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts); Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 429 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 14
States / cities: Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 11 more

Conditions: Prostate Cancer
Interventions: ZD4054 (Zibotentan), Docetaxel, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Buffalo, New York • Greenville, South Carolina • Nashville, Tennessee

Conditions: HER2-positive Breast Cancer
Interventions: Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Trastuzumab emtansine; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Non-small Cell Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB, Stage IV Non-small Cell Lung Cancer, EGFR Negative Non-Small Cell Lung Cancer
Interventions: Ceritinib, Docetaxel; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Conditions: Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
Interventions: Pembrolizumab/Vibostolimab Co-Formulation, Pembrolizumab, Lenvatinib, 5-Fluorouracil, Cisplatin, Paclitaxel, Gemcitabine, Carboplatin, Docetaxel, Bevacizumab, Capecitabine, Oxaliplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 14
States / cities: Anchorage, Alaska • Duarte, California • Orange, California + 11 more

Search by objective public record fields.

Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Docetaxel in Node Positive Adjuvant Breast Cancer

Low-Dose Taxotere® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer

A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer

A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors

Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)